Co-Diagnostics, Inc. (CODX)
NASDAQ: CODX · Real-Time Price · USD
0.3250
-0.0087 (-2.61%)
At close: Nov 25, 2025, 4:00 PM EST
0.3370
+0.0120 (3.69%)
After-hours: Nov 25, 2025, 7:57 PM EST
Co-Diagnostics Revenue
Co-Diagnostics had revenue of $145.38K in the quarter ending September 30, 2025, a decrease of -77.32%. This brings the company's revenue in the last twelve months to $507.89K, down -93.06% year-over-year. In the year 2024, Co-Diagnostics had annual revenue of $3.92M, down -42.53%.
Revenue (ttm)
$507.89K
Revenue Growth
-93.06%
P/S Ratio
21.44
Revenue / Employee
$3,848
Employees
132
Market Cap
19.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.92M | -2.90M | -42.53% |
| Dec 31, 2023 | 6.81M | -27.41M | -80.09% |
| Dec 31, 2022 | 34.22M | -63.67M | -65.04% |
| Dec 31, 2021 | 97.89M | 23.33M | 31.30% |
| Dec 31, 2020 | 74.55M | 74.34M | 34,579.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CODX News
- 5 days ago - Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health - PRNewsWire
- 7 days ago - Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA - PRNewsWire
- 12 days ago - Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Co-Diagnostics Reports Third Quarter 2025 Financial Results - PRNewsWire
- 19 days ago - Co-Diagnostics, Inc. (CODX) Discusses Saudi Arabia Joint Venture, AI Initiatives and Diagnostics Technology Developments Transcript - Seeking Alpha
- 20 days ago - Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd - PRNewsWire
- 22 days ago - Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform - PRNewsWire
- 25 days ago - Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast - PRNewsWire